Antibiotic prescribing and bacterial infection in COVID-19 inpatients in Southeast Asia: a systematic review and meta-analysis

被引:0
|
作者
Chanapal, Achiraya [1 ,2 ]
Cheng, Hung-Yung [1 ]
Lambert, Helen [1 ]
Cong, Wenjuan [1 ]
机构
[1] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, 39 Whatley Rd, Bristol BS8 2PS, England
[2] Univ Phayao, Sch Med, Phayao 56000, Thailand
来源
JAC-ANTIMICROBIAL RESISTANCE | 2024年 / 6卷 / 03期
基金
美国国家卫生研究院;
关键词
ANTIMICROBIAL RESISTANCE; CARE;
D O I
10.1093/jacamr/dlae093
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The prescribing of antibiotics to treat COVID-19 patients has been observed to occur frequently, often without clear justification. This trend raises concerns that it may have exacerbated antimicrobial resistance (AMR). Despite longstanding concerns over AMR in Southeast Asian countries, data on this issue are notably lacking.Objectives To explore the impact of COVID-19 on antibiotic prescribing, bacterial infection prevalence and common resistant pathogens in COVID-19 inpatients.Methods We searched PubMed, EMBASE, Web of Science and ThaiJO (a Thai academic database) to identify studies conducted in ASEAN member countries and published between December 2019 and March 2023. Screening and data extraction were done by two independent reviewers, with results synthesized using random-effects meta-analyses and descriptive statistical analyses. This review was registered with PROSPERO (CRD42023454337).Results Of the 29 studies (19 750 confirmed COVID-19 cases) included for final analysis, the antibiotic prescribing rate was 62.0% (95%CI: 46.0%-76.0%) with a prescribing rate of 58.0% (21.0%-91.0%) in mild/moderate cases versus 91.0% (82.0%-98.0%) in severe/critical cases. Notably, 80.5% of antibiotics prescribed fall under the WHO AWaRe 'Watch' list, followed by 'Access' at 18.4% and 'Reserve' at 1.0%. The reported bacterial infection prevalence was 16.0% (7.0%-29.0%), with Acinetobacter baumannii being the most common resistant bacterium at 7.7%. Singapore was notable for its lower antibiotic prescribing rate of 17.0% and a lower bacterial infection rate of 10.0%.Conclusions High antibiotic prescribing rates, disproportionate to bacterial infections and varying practices for COVID-19 inpatients across countries highlight the urgent need for this region to collaborate to tackle and mitigate AMR.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Mortality risk in patients with obesity and COVID-19 infection: a systematic review and meta-analysis
    Haber, Rachelle
    Ghezzawi, Malak
    Puzantian, Houry
    Haber, Marc
    Saad, Sacha
    Ghandour, Yara
    El Bachour, Joseph
    Yazbeck, Anthony
    Hassanieh, Ghinwa
    Mehdi, Celine
    Ismail, Dima
    Abi-Kharma, Elias
    El-Zein, Ola
    Khamis, Assem
    Chakhtoura, Marlene
    Mantzoros, Christos
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 155
  • [42] The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis
    Teshome, Amare
    Adane, Aynishet
    Girma, Biruk
    Mekonnen, Zeleke A.
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [43] COVID-19 depression and its risk factors in Asia Pacific - A systematic review and meta-analysis
    Balakrishnan, Vimala
    Ng, Kee Seong
    Kaur, Wandeep
    Govaichelvan, Kumanan
    Lee, Zhen Lek
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 298 : 47 - 56
  • [44] Prevalence of anxiety and depression in South Asia during COVID-19: A systematic review and meta-analysis
    Hossain, Md Mahbub
    Rahman, Mariya
    Trisha, Nusrat Fahmida
    Tasnim, Samia
    Nuzhath, Tasmiah
    Hasan, Nishat Tasnim
    Clark, Heather
    Das, Arindam
    McKyer, E. Lisako J.
    Ahmed, Helal Uddin
    Ma, Ping
    HELIYON, 2021, 7 (04)
  • [45] The relationship of headache as a symptom to COVID-19 survival: A systematic review and meta-analysis of survival of 43,169 inpatients with COVID-19
    Gallardo, Victor J.
    Shapiro, Robert E.
    Caronna, Edoardo
    Pozo-Rosich, Patricia
    HEADACHE, 2022, 62 (08): : 1019 - 1028
  • [46] Tocilizumab for severe COVID-19: a systematic review and meta-analysis
    Lan, Shao-Huan
    Lai, Chih-Cheng
    Huang, Hui-Ting
    Chang, Shen-Peng
    Lu, Li-Chin
    Hsueh, Po-Ren
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (03)
  • [47] Asthma and COVID-19 risk: a systematic review and meta-analysis
    Sunjaya, Anthony P.
    Allida, Sabine M.
    Di Tanna, Gian Luca
    Jenkins, Christine R.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (03)
  • [48] Epidemiological characteristics of COVID-19: a systematic review and meta-analysis
    Khalili, Malahat
    Karamouzian, Mohammad
    Nasiri, Naser
    Javadi, Sara
    Mirzazadeh, Ali
    Sharifi, Hamid
    EPIDEMIOLOGY AND INFECTION, 2020, 148
  • [49] Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis
    Aziz, Muhammad
    Haghbin, Hossein
    Abu Sitta, Emad
    Nawras, Yusuf
    Fatima, Rawish
    Sharma, Sachit
    Lee-Smith, Wade
    Duggan, Joan
    Kammeyer, Joel A.
    Hanrahan, Jennifer
    Assaly, Ragheb
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (03) : 1620 - 1630
  • [50] Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis
    Pravash Budhathoki
    Dhan Bahadur Shrestha
    Era Rawal
    Sitaram Khadka
    SN Comprehensive Clinical Medicine, 2020, 2 (12) : 2600 - 2620